This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Why The Cooper Companies (COO) Might Surprise This Earnings Season
by Zacks Equity Research
The Cooper Companies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?
by Zacks Equity Research
CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.
DaVita (DVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.
Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?
by Zacks Equity Research
DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.
Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) Specialty Health unit is likely to drive the company's top line in the third quarter of fiscal 2018.
H&R Block (HRB) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Core business focus is likely to drive H&R Block's (HRB) Q2 earnings although macroeconomic challenges remain impediments
Will CooperVision Drive Cooper Companies' (COO) Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fourth quarter is expected to gain from strength in the CVI & CSI segments.
Only 4 Dental Stocks to Buy Amid MedTech Regulatory Woes
by Zacks Equity Research
After a stellar five-year run on the bourse, the performance of the dental industry has taken a hit in the last two years.
Patterson Companies (PDCO) Q2 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies' (PDCO) solid dental segment is a positive. The company anticipates troubles in its technology equipment business to persist through fiscal 2018.
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.
What's in the Cards for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) might gain from continued growth in its companion diagnostics portfolio in Q3.
Will GNC Holdings (GNC) Disappoint This Earnings Season?
by Zacks Equity Research
Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.
Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.
Why Is Cooper Companies (COO) Down 7.7% Since the Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Momentum Stocks to Pick Despite MedTech Policy Debacle
by Zacks Equity Research
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Dental Faces Regulatory Challenges: Only 5 Stocks to Pick
by Zacks Equity Research
Owing to the adversities in the medical universe, market watchers have adopted a bearish stance toward the dental space. These are the only five dental stocks that are expected to beat the ongoing MedTech gloom.
Top Ranked Momentum Stocks to Buy for September 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 8th:
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
Why Is Cooper Companies (COO) Up 7.9% Since the Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can the Rally in Cooper Companies (COO) Shares Continue?
by Zacks Equity Research
Cooper Companies Inc (COO) has been on the move lately as the stock has risen by 17.1% in the past four weeks, and it is currently trading well above its 20-Day SMA
Cooper (COO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report second-quarter fiscal 2017 results after the market closes on Jun 1.
Align Technology (ALGN) Rises: Stock Adds 7.5% in Session
by Zacks Equity Research
Align Technology, Inc. (ALGN) rose over 7% in the last trading session.
Cooper Companies (COO) Increase Share Repurchase Program
by Zacks Equity Research
The Cooper Companies, Inc. (COO) recently announced that it has approved a $500.0 million increase in its ongoing share repurchase program.
Cooper Companies (COO) Receives ISO 15189 Accreditation
by Zacks Equity Research
The Cooper Companies Inc. (COO) announced that its London and Nottingham-based laboratories received the International Organization for Standardization 15189 accreditation.
The Cooper Companies (COO) Beats Earnings Estimates in Q1
by Zacks Equity Research
The Cooper Companies Inc.(COO) reported adjusted earnings of $1.93 in first-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 7 cents and improving 5.5% on a year-over-year basis.